Unit | Parasite Chemotherapy

The Parasite Chemotherapy Unit is the drug discovery centre for protozoan parasites. It draws on over 20 years of experience in parasite propagation to assess the chemotherapeutic potential of compounds against Plasmodium spp., African trypanosomes, Trypanosoma cruzi and Leishmania. The research of the Parasite Chemotherapy groups comprises three main areas:

Drug discovery work

A substantial part of the research concentrates on developing novel in vitro assays and in vivo models. Drug discovery activities are complemented by preclinical studies on drug absorption and pharmacokinetics. Further, molecular biology and bioinformatic approaches target the mechanisms of drug resistance and the mode of drug action. The unit has a screening mandate from the Medicines for Malaria Venture (MMV) Foundation and became the main centre for WHO/TDR for in vitro screening against protozoan parasites.

Pascal Mäser

Pascal Mäser, Associate Professor, PhD

Eastern Africa Network for Trypanosomiasis (EANETT)

Besides working on new drugs, the group also collaborates with African partner institutes in the Eastern Africa Network for Trypanosomosis (EANETT) in the area of sleeping sickness research and control. The Swiss Agency for Development and Co-operation (SDC) awarded the network a second phase of support for 2004–2006. A major goal for this phase will be to involve the network in international activities with access to additional funding.

Tsetse Transmission

A further element of activities deals with studies of trypanosome transmission through the tsetse fly vector to gain more knowledge about the life cycle of the parasite and the function of certain surface proteins.

The Parasite Chemotherapy Unit (PCU) is a drug discovery center for protozoan parasites. We have over 20 years of experience in assay development and drug efficacy testing for the causative agents of malaria (Plasmodium spp.), African sleeping sickness (Trypanosoma brucei), Chagas' disease (T. cruzi), Leishmanioses (Leishmania spp.) and diarrhea (Entamoeba and Giardia). Primary and secondary in vitro tests are combined with mouse models of the diseases (for African trypanosomes and malaria) and with molecular approaches on the mechanisms of drug action and drug resistance. The PCU is closely collaborating with product-development-partnerships such as MMV, DNDi or GALVmed, with academic partners from all over the globe, and with pharma companies. The PCU has been instrumental to the development of several clinical candidates including fexinidazole for human African trypanosomiasis (HAT) and artefenomel for malaria. The PCU was founded by Prof. Reto Brun and is led by Prof. Pascal Mäser.

Arafa R.K et al. New antiparasitic flexible triaryl diamidines, their prodrugs and aza analogues: synthesis, in vitro and in vivo biological evaluation, and molecular modelling studies. Eur J Med Chem. 2021;222:113625. DOI: 10.1016/j.ejmech.2021.113625

Bevkal S, Naguleswaran A, Rehmann R, Kaiser M, Heller M, Roditi I. An Alba-domain protein required for proteome remodelling during trypanosome differentiation and host transition. PLoS Pathog. 2021;17:e1009239. DOI: 10.1371/journal.ppat.1009239

Boberg M, Cal M, Kaiser M, Jansson-Lofmark R, Mäser P, Ashton M. Enantiospecific antitrypanosomal in vitro activity of eflornithine. PLoS Negl Trop Dis. 2021;15(7):e0009583. DOI: 10.1371/journal.pntd.0009583

Brand M et al. Antiprotozoal structure-activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action. Angew Chem Int Ed Engl. 2021(in press). DOI: 10.1002/anie.202102153

Brooke D.P et al. Truncated S-MGBs: towards a parasite-specific and low aggregation chemotype. RSC Med Chem. 2021;12(8):1391. DOI: 10.1039/d1md00110h